Arrowhead Research Corp (NASDAQ:ARWR) shares are soaring in early trading this morning, after the company announced great news concerning their drug, ARC-520. ARC-520 is a treatment for the Hepatitis B virus, a virus that affects the liver and causes acute and chronic infections in sufferers.
Arrowhead Research Corp (NASDAQ:ARWR) unveiled at HEP DART 2015 that ARC-520 has shown to be very effective on treating chimpanzees with Hepatitis B. In fact, the drug, when used alongside nucleoside analags, showed signs of immune reactivation in 7 out of 9 treated chimps (78%).
Arrowhead Research Corp (NASDAQ:ARWR) CEO Christopher Anzalone, Ph.D. said, “The hepatitis B virus causes infected cells to produce several proteins that suppress the host immune system, and, therefore, enable chronic viral infection by removing immune control. Our goal with ARC-520 is to reduce expression of those proteins and thereby enable reconstitution of the immune system. We now have shown that ARC-520 can do that, and not just in 1 or 2 infected chimps, but in 7 of the 9 chimps we treated, and this is a big deal.”
Read more....Labels: ARC-520, Arrowhead, HBV drugs in development